Restricted accessCase reportFirst published online 2019-7
Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab
We report an unusual case of spontaneous intramuscular hematoma associated with antiproteinase 3 antibody in a patient with metastatic squamous cell carcinoma receiving nivolumab and the medical literature is reviewed.
BrahmerJRDrakeCGWollnerIet al.Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol2010; 28: 3167–3175.
2.
TopalianSLHodiFSBrahmerJRet al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med2012; 366: 2443–2454.
3.
TopalianSLSznolMMcDermottDFet al.Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol2014; 32: 1020–1030.
4.
GibneyGTKudchadkarRRDeContiRCet al.Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res2015; 21: 712–720.
5.
RobertCLongGVBradyBet al.Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med2015; 372: 320–330.
6.
BorghaeiHPaz-AresLHornLet al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med2015; 373: 1627–1639.
7.
BrahmerJReckampKLBaasPet al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med2015; 373: 123–135.
8.
GettingerSNHornLGandhiLet al.Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol2015; 33: 2004–2012.
9.
RizviNAMazieresJPlanchardDet al.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol2015; 16: 257–265.
10.
GettingerSRizviNAChowLQet al.Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol2016; 34: 2980–2987.
11.
FerrisRLBlumenscheinGJrFayetteJet al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med2016; 375: 1856–1867.
12.
SeiwertTYBurtnessBMehraRet al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol2016; 17: 956–965.
13.
AnsellSMLesokhinAMBorrelloIet al.PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med2015; 372: 311–319.
14.
SharmaPCallahanMKBonoPet al.Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol2016; 17: 1590–1598.
15.
McDermottDFDrakeCGSznolMet al.Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol2015; 33: 2013–2020.
16.
MotzerRJRiniBIMcDermottDFet al.Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol2015; 33: 1430–1437.
17.
MotzerRJEscudierBMcDermottDFet al.Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med2015; 373: 1803–1813.
18.
MuroKChungHCShankaranVet al.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol2016; 17: 717–726.
19.
LoochtanAINickolichMSHobson-WebbLD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve2015; 52: 307–308.
20.
Martin-LiberalJFurnessAJJoshiKet al.Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother2015; 64: 765–767.
21.
NaritaTOisoNTaketomoYet al.Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. J Dermatol2016; 43: 210–214.
22.
RossiESgambatoAChiaraGet al.Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. Expert Rev Clin Pharmacol2016; 9: 419–423.
23.
SreenivasMNihalAEttlesDF. Chronic haematoma or soft-tissue neoplasm? A diagnostic dilemma. Arch Orthop Trauma Surg2004; 124: 495–497.
24.
LiuPTLeslieKOBeauchampCPet al.Chronic expanding hematoma of the thigh simulating neoplasm on gadolinium-enhanced MRI. Skeletal Radiol2006; 35: 254–257.
NegoroKUchidaKYayamaTet al.Chronic expanding hematoma of the thigh. Joint Bone Spine2012; 79: 192–194.
27.
EverhartJSFajoluOKMayersonJL. Spontaneous, chronic expanding posterior thigh hematoma mimicking soft-tissue sarcoma in a morbidly obese pregnant woman. Am J Orthop (Belle Mead NJ)2015; 44: E29–E31.
28.
JenningsJGChangLSavigeJA. Anti-proteinase 3 antibodies, their characterization and disease associations. Clin Exp Immunol1994; 95: 251–256.
29.
WildeCGSnableJLGriffithJEet al.Characterization of two azurphil granule proteases with active-site homology to neutrophil elastase. J Biol Chem1990; 265: 2038–2041.
30.
ManusowJSKhojaLPesinNet al.Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer2014; 2: 41–41.
